DIRS.INFO The most relevant business & tech news

On a more positive note, Guggenheim upgraded GSK to buy thanks to strength across multiple product pipelines. Elsewhere, RBC upgraded Lyft to outperform, calling for a major rally ahead. Analyst Brad Erickson upgraded Lyft shares to outperform from sector perform, and raised his price target by $6 to $23, implying roughly 40.7% potential increase. — Pia Singh 6:10 a.m.: DoorDash upgraded by RBC on new partnerships potential, higher order growth RBC Capital Markets upgraded DoorDash to outperform from sector perform. Analyst Seamus Fernandez upgraded shares to buy from neutral and assigned a £20.31 price target, representing 21% upside to GSK's latest close.

Persons: Guggenheim, Wells Fargo, Timur Braziler, Braziler, — Pia Singh, Lyft, Brad Erickson, Erickson, Seamus Fernandez, Fernandez, Citi downgrades Ferrari, Ferrari, Harald Hendrikse, Fred Imbert Organizations: CNBC, Citi, Ferrari, GSK, RBC, Popular, RBC Capital Markets RBC Capital Markets, DASH, Capital Markets, Guggenheim Securities, drugmaker GSK, Guggenheim Locations: Wells Fargo, Puerto Rico, U.S, Wells, Shingrix, Arexvy, Milan

☆ GSK raises annual forecasts powered by strong Arexvy launch
▼ + stars: | 2023-11-01 | by ( ) www.reuters.com time to read: +2 min

Analysts expect the British drugmaker's RSV vaccine Arexvy to power future growth, amid worries about the strength of its pipeline of drugs in development and costly U.S. litigation over discontinued heartburn drug Zantac. Arexvy, launched in the United States recently, is expected to garner full-year sales of between 900 million pounds to 1 billion pounds ($1.22 billion), GSK said. For the third quarter, the shot recorded sales of 709 million pounds, trouncing analysts' expectations of 358 million pounds, according to a company-compiled consensus. Meanwhile, sales are seen to rise by 12% to 13% in 2023 compared with earlier expectations of 8% to 10%. For the reported quarter, sales of Shingrix, the company's top-selling drug to treat shingles, generated 825 million pounds, below market estimates of 868 million pounds.

Persons: Dado Ruvic, Eva Mathews, Subhranshu Sahu, Tomasz Janowski Organizations: GSK, GlaxoSmithKline, REUTERS, Thomson Locations: United States, Bengaluru

☆ GSK lifts annual forecasts on strong launch of RSV vaccine
▼ + stars: | 2023-11-01 | by ( Eva Mathews | ) www.reuters.com time to read: +3 min

Arexvy, launched in the United States recently, recorded third quarter sales of 709 million pounds ($862 million), trouncing analysts' expectations of 358 million pounds, according to a company-compiled consensus. GSK accounts for close to two-thirds of RSV shots given in the United States since early September, according to IQVIA data. Full-year sales are seen between 900 million pounds and 1 billion pounds for the shot, GSK said. The company faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware and scheduled for trial starting January 2024. For the third quarter, Shingrix, the company's top-selling drug for shingles, generated 825 million pounds in sales.

Persons: Dado Ruvic, Abrysvo, Dani Saurymper, Emma Walmsley, Eva Mathews, Maggie Fick, Tomasz Janowski, Mark Potter Organizations: GSK, GlaxoSmithKline, REUTERS, stg, CVS, Pfizer, Pacific Asset Management, GSK's, Thomson Locations: London, United States, U.S, Europe, Japan, Delaware, Bengaluru

REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsLONDON/SHANGHAI Oct 9 (Reuters) - China's largest vaccines company Zhifei (300122.SZ) will pay British drugmaker GSK (GSK.L) 2.5 billion pounds ($3.05 billion pound) for the exclusive rights to distribute GSK's shingles vaccine in the world's No.2 pharmaceuticals market. The deal with Zhifei is part of its efforts to reach more 4 billion pounds ($4.88 billion) in sales by 2026, GSK said. Zhifei will purchase volumes of Shingrix with a value to GSK worth 2.5 billion pounds over an initial three-year period, GSK said. Zhifei shares were up as much as 20% to 58.40 yuan ($8.00) following the filing, their highest point since March 27. Shingrix is currently GSK's biggest product and strongest growth driver, taking in 1.71 billion pounds in first-half sales, up 20% from a year prior.

Persons: Dado Ruvic, Zhifei, Shingrix, Maggie Fick, Andrew Silver, Eva Mathews, Savio D'Souza, Louise Heavens Organizations: GSK, GlaxoSmithKline, REUTERS, British, AstraZeneca, Zhifei, Barclays, Reuters, Thomson Locations: SHANGHAI, China, United States, London, Shanghai, Bengaluru

☆ GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
▼ + stars: | 2023-07-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

GlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company's new RSV vaccine to start off slower than it did for its blockbuster shingles shot. Last month, GSK's RSV shot became the first to win approval in the U.S. and European Union for the treatment of adults 60 and above. The company has not provided estimates for how much revenue the RSV shot will rake in this year following its launch. GSK's vaccine against shingles, a viral infection that causes a painful rash, is the company's top-selling drug. Investors are hoping that Shingrix and GSK's RSV shot will help offset patent expirations for some of the company's blockbuster HIV drugs in a few years.

Persons: Emma Walmsley, Walmsley Organizations: GSK, Union, U.S, European Union, Investors Locations: London, U.S, Japan, Canada

GSK reckons the spin-off has allowed the company to sharpen its focus on vaccines and infectious diseases and with $7 billion generated by the Haleon spin-off, it can fund deals to bolster a lacklustre drug pipeline. The company also reported an adjusted profit of 38.8 pence per share for the quarter, on sales of about 7.18 billion pounds ($9.26 billion). Analysts were expecting a profit of 34.7 pence per share on sales of about 6.77 billion pounds, according to company-compiled consensus estimates. Sales of Shingrix, the company's top-selling drug, generated 880 million pounds, beating analyst estimates of 872 million pounds. Sales of HIV treatments generated 1.58 billion in the quarter, ahead of the company-compiled consensus of about 1.5 billion pounds in the quarter.

Persons: Zantac, Emma Walmsley, Walmsley, Markus Manns, Dani Saurymper, Maggie Fick, Radhika Anilkumar, Janane Venkatraman, Savio D'Souza, Josephine Mason Organizations: GSK, British, Analysts, U.S, Union Investment, Pacific Asset Management, Thomson Locations: London, Bengaluru

☆ GSK beats first-quarter profit, revenue estimates
▼ + stars: | 2023-04-26 | by ( ) www.reuters.com time to read: +2 min

LONDON, April 26 (Reuters) - GSK (GSK.L) on Wednesday beat expectations for its first-quarter revenue and profit, helped by sales of its blockbuster shingles vaccine Shingrix. The London-listed drugmaker reported adjusted profit of 37 pence per share on revenue of about 7 billion pounds ($8.70 billion). Analysts were expecting 33.2 pence per share on revenue of about 6.5 billion pounds, according to company-compiled consensus estimates. In February, GSK predicted sales growth would increase by 6% to 8% and adjusted operating profit to increase by 10% to 12%, at constant exchange rates in 2023, versus 2022. GSK is also leaning in part on its vaccine for RSV, which leads to thousands of hospitalisations and deaths each year.

☆ How GSK plans to replenish its depleted medicine cabinet
▼ + stars: | 2023-03-15 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

GSK has since suffered a series of clinical trial setbacks in its cancer drugs portfolio, most recently last year involving ovarian cancer drug Zejula and blood cancer drug Blenrep. BLOCKBUSTER POTENTIALAnalysts say that despite a string of strong quarterly earnings, lingering concerns over the company's drug pipeline reflect in GSK's share price. The investor said he does not see enough GSK drugs, either on the market or in development, with potential to be a so-called "blockbusters" with annual sales exceeding $1 billion. But Wood said the overhauled R&D department has put GSK in a strong position to meet growth targets. U.S. regulatory approval on GSK's vaccine, and a rival vaccine developed by Pfizer, is expected in May.

☆ With positive combo meningococcal vaccine data, GSK eyes US approval
▼ + stars: | 2023-03-14 | by ( ) www.reuters.com time to read: +3 min

If approved, the combo vaccine could simplify the immunisation schedule in the United States and likely expand GSK's already dominant market share there for vaccines used to prevent illnesses caused by meningococcal bacteria. These responses were compared to participants who received GSK's approved vaccines, Bexsero and Menveo. In the United States, a four-shot regimen of Bexsero and Menveo is needed to protect against the five most common strains of meningococcal bacteria. There is no combination vaccine on the market - a gap GSK intends to fill with the new combination. GSK has the world's largest vaccine R&D department and has a broad portfolio of shots, including its blockbuster shingles vaccine Shingrix.

On Wednesday, the company reported adjusted fourth quarter profit of 25.8 pence per share on sales of about 7.4 billion pounds ($9.11 billion). At 0900 GMT, GSK shares were up 0.4% outperforming the FTSE 100 which was up 0.3%. U.S. litigation over the heartburn drug Zantac has also spooked investors, hurting GSK's shares in the second half of 2022. "Nevertheless, against the backdrop of recent performance, and without any contribution from Covid-19, GSK’s 2023 guidance demonstrates some improved momentum," he said. GSK's shares have lagged most of its rivals in recent years.

Companies GSK plc FollowAstraZeneca PLC FollowFeb 1 (Reuters) - GSK (GSK.L) on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix. That beat the 21.2 pence per share on sales of about 7.1 billion pounds expected by analysts in a company-compiled consensus. Shingrix generated 769 million pounds over the quarter, topping the 748 million in the GSK-compiled consensus estimates. GSK, now solely focused on vaccines and medicines, on Wednesday forecast 2023 adjusted operating profit to climb by 10% to 12% on sales up 6% to 8%. The company said that it also does not expect any significant COVID-19 pandemic-related sales in 2023, after the its COVID solutions unit generated 2.4 billion pounds last year.

☆ GSK reports Q4 profit, sales beat Wall Street estimates
▼ + stars: | 2023-02-01 | by ( ) www.reuters.com time to read: +1 min

Companies GSK plc FollowFeb 1 (Reuters) - GSK (GSK.L) on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix. The London-listed drugmaker, which executed a long-scripted overhaul with the spinoff of its consumer health unit last July, reported adjusted profit of 25.8 pence per share on sales of about 7.4 billion pounds ($9.11 billion). Analysts were expecting 21.2 pence per share on sales of about 7.1 billion pounds, company-compiled consensus estimates showed. Shingrix generated 769 million pounds over the quarter, topping the 748 million in the GSK-compiled consensus estimates. ($1 = 0.8120 pounds)Reporting by Maggie Fick and Natalie Grover; editing by Jason NeelyOur Standards: The Thomson Reuters Trust Principles.

LONDON, Feb 1 (Reuters) - GSK (GSK.L) chief executive Emma Walmsley on Wednesday made replenishing the drugmaker's pipeline of vaccines and therapies her number-one priority. But analysts say there is not enough in the medicine cabinet to keep the momentum going even beyond the next few years. Meanwhile, analysts say the market for Shingrix will eventually become saturated, further limiting the company's growth prospects. GSK shares lagR&D SPENDGSK's spending on R&D has long lagged behind its peers, something activist investor Elliott highlighted in a 2021 letter pressuring the company to make sweeping changes. Lucy Coutts, investment director at wealth management firm JM Finn, which holds GSK shares, there is hope the company will eventually deliver a streamlined and specialist portfolio of blockbuster drugs.

In 2022, drugmakers raised prices on more than 1,400 drugs according to data published by 46brooklyn, a drug pricing non-profit that is related to 3 Axis. The median drug price increase was 4.9% last year, while the average increase was 6.4%, according to 46brooklyn. Antonio Ciaccia, president of 3 Axis, said that drugmakers have focused on launching their drugs at higher prices because of the attention paid to annual price increases. More drug prices are likely to be announced over the course of January - historically the biggest month for drugmakers to raise prices. Sanofi plans to raise prices on 14 of its drugs or vaccines.

☆ GSK lifts earnings view again after forecast-beating quarter
▼ + stars: | 2022-11-02 | by ( Natalie Grover | ) www.reuters.com time to read: +2 min

[1/2] GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. Shingrix generated sales of 760 million pounds ($873 million) compared with the GSK-compiled analyst consensus forecast for 685 million pounds. In July, GSK had predicted 2022 sales growth of 6% to 8% and adjusted operating profit to climb by 13% to 15%, both increases on forecasts issued in February. GSK said it had incurred a charge of 45 million pounds in the third quarter, primarily reflecting provisions for increased legal fees related to heartburn drug Zantac. Originally marketed by a forerunner of GSK, Zantac has been sold by several companies at different times, including Pfizer (PFE.N), Boehringer Ingelheim and Sanofi (SASY.PA) as well as a plethora of generic drugmakers.

☆ GSK lifts 2022 forecast again after stronger than expected quarter
▼ + stars: | 2022-11-02 | by ( Natalie Grover | ) www.reuters.com time to read: +1 min

[1/2] GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File PhotoNov 2 (Reuters) - GSK (GSK.L) on Wednesday GSK (GSK.L) on Wednesday smashed analysts' estimates for third-quarter earnings, driven by higher sales of its blockbuster shingles vaccine, Shingrix. This quarter, Shingrix blew past expectations by generating sales of 760 million pounds ($872.86 million) compared to the GSK-compiled consensus of 685 million pounds. GSK reported third-quarter adjusted profit of 46.9 pence on sales of about 7.83 billion pounds, compared with a company-compiled analyst consensus of 40.1 pence on sales of 7.32 billion pounds. Previously in July, GSK had predicted that 2022 sales would rise 6% to 8% and adjusted operating profit to climb by 13% to 15%, boosting a forecast for 2022 guidance issued in February.

☆ New GSK shines brighter with another forecast upgrade
▼ + stars: | 2022-11-02 | by ( Natalie Grover | ) www.reuters.com time to read: +3 min

Shingrix generated quarterly sales of 760 million pounds ($873 million), compared with the GSK-compiled analyst consensus forecast for 685 million pounds. GSK shares hit a 2-1/2 month high of 1,470.2 pence in early trade and were last up 1% at 1,461.3 pence. GSK said it had incurred a charge of 45 million pounds in the third quarter, primarily reflecting provisions for increased legal fees related Zantac. Originally marketed by a forerunner of GSK, Zantac has been sold by companies including Pfizer (PFE.N), Boehringer Ingelheim and Sanofi (SASY.PA), as well as many generic drugmakers. GSK reported a third-quarter adjusted profit of 46.9 pence per share on sales of about 7.83 billion pounds, topping analysts' forecasts for 40.1 pence and 7.32 billion pounds.

Search resuls for: "Shingrix"

17 mentions found